PLYMOUTH, Minn., April 8, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced the initiation of a supply agreement with MEDRAD Interventional™/Possis®. Under terms of the agreement, MEDRAD will make available their Cotavance™ peripheral drug-eluting balloon angioplasty catheter with Paccocath® technology for study in combination with ev3’s SilverHawk® and TurboHawk™ Plaque Excision Systems for use in the DEFINITIVE AR European pilot study for treating lower extremity peripheral arterial disease (PAD).
